| 靶向药物联合应用对肝癌细胞SK-Hep-1增殖的影响及其机制 |
| |
| 引用本文： | 朱晓霞,贾瑜琦,刘畅,弓韬,李高鹏,张宏伟,于保锋.靶向药物联合应用对肝癌细胞SK-Hep-1增殖的影响及其机制[J].肿瘤防治研究,2022,49(11):1126-1133. |
| |
| 作者姓名： | 朱晓霞 贾瑜琦 刘畅 弓韬 李高鹏 张宏伟 于保锋 |
| |
| 作者单位： | 1. 030001 太原，山西医科大学基础医学院生物化学与分子生物学教研室；2. 046000 长治，长治医学院基础部生物化学与分子生物学教研室；3. 030006 太原，山西白求恩医院普通外科；4. 030013 太原，山西省肿瘤医院血液科 |
| |
| 基金项目： | 国家自然科学基金（30901821, 81172 1 3 6 ）；山西省自然科学基金（201701D121165, 201901D111190） ； 山西青年科技研究基金（201801D221069）；山西省回国留学人员科研资助项目（2020-194, 2021-165）；细胞生理学教育部重点实验室（山西医科大学）开放基金（KLMEC/SXMU-202011）；山西省“1331工程”重点学科建设计划项目（1331KSC）；山西省优秀青年基金（201901D211547）；山西省卫生健康委科研课题（2019059）；“136”院级开放基金（2021YZ03） |
| |
| 摘 要： | 目的 探讨靶向药物联合应用对多驱动基因调控增殖的肝癌细胞SK-Hep-1的影响及作用机制。方法 利用对肝癌细胞SK-Hep-1敏感的靶向药物（HG6-64-1、dasatinib、crizotinib、sunitinib）绘制单靶点动力学分析曲线和双相分析曲线，对SK-Hep-1细胞进行动力学分析；Western blot法检测这些靶向药物对SK-Hep-1细胞关键信号通路的影响；MTT法检测这些药物单用和联合应用对SK-Hep-1细胞增殖的影响。结果 与单靶点动力学分析曲线比较，双相分析曲线可更好拟合靶向药物对肝癌细胞SK-Hep-1的影响，并且预测出HG6-64-1、dasatinib和MK-2206三药联合应用能有效抑制SK-Hep-1细胞增殖。结论 双相动力学分析可以更好地定量描述多驱动增殖的肝癌细胞SK-Hep-1对靶向治疗的反应，联合使用HG6-64-1、dasatinib和MK-2206是治疗肝癌潜在的药物组合。
|
| 关 键 词： | 肝细胞癌 双相动力学分析 多驱动增殖 靶向药物 作用机制 药物联合 |
| 收稿时间： | 2022-02-23 |
Effects and Mechanisms of Combined Application of Molecular Targeted Drugs on Proliferation of Hepatocellular Carcinoma SK-Hep-1 Cells |
| |
| ZHU Xiaoxia,JIA Yuqi,LIU Chang,GONG Tao,LI Gaopeng,ZHANG Hongwei,YU Baofeng.Effects and Mechanisms of Combined Application of Molecular Targeted Drugs on Proliferation of Hepatocellular Carcinoma SK-Hep-1 Cells[J].Cancer Research on Prevention and Treatment,2022,49(11):1126-1133. |
| |
| Authors: | ZHU Xiaoxia JIA Yuqi LIU Chang GONG Tao LI Gaopeng ZHANG Hongwei YU Baofeng |
| |
| Affiliation: | 1. Department of Biochemistry and Molecular Biology, Basic Medical College, Shanxi Medical University, Taiyuan 030001, China; 2. Department of Biochemistry and Molecular Biology, Changzhi Medical College, Changzhi 046000, China; 3. General Surgery Department, Shanxi Bethune Hospital, Taiyuan 030006, China; 4. Department of Hematology, Shanxi Cancer Hospital, Taiyuan 030013, China |
| |
| Abstract: | Objective To study the effects and mechanisms of molecular targeted drug combination on multidriven proliferation hepatocellular carcinoma SK-Hep-1 cells. Methods Four molecular targeted drugs (HG6-64-1, Dasatinib, Crizotinib, and Sunitinib) were used to treat SK-Hep-1 cells, and the monophasic kinetic analysis curve and two-phase analysis curve were drawn. Western blot analysis was used to detect the effects of the above drugs on key signaling pathways in SK-Hep-1 cells. MTT assay was used to detect the effects of the above drugs and their combination on the proliferation of SK-Hep-1 cells. Results Compared with the monophasic kinetic analysis curve, the biphase analysis curve could better fit the effects of molecular targeted drugs on SK-Hep-1 cells, which predicted that the combination of HG6-64-1, Dasatinib, and MK-2206 could effectively inhibit the proliferation of SK-Hep-1 cells. Conclusion Two-phase kinetic analysis can quantitatively describe the response of multi-driven proliferation hepatocellular carcinoma SKHep-1 cells to molecular targeted therapy. The combination of HG6-64-1, Dasatinib, and MK-2206 is a potential drug combination for the treatment of hepatocellular carcinoma. |
| |
| Keywords: | Hepatocellular carcinoma Two-phase dynamics analysis Multi-driven proliferation Molecular targeted drug Mechanism of action Drug combination |
|
| 点击此处可从《肿瘤防治研究》浏览原始摘要信息 |
|
点击此处可从《肿瘤防治研究》下载全文 |
|
